Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)

Diagnosis ALS
Study phase Completed
Participating centres UMC Utrecht

A prospective, multicenter, randomized, double-blind, placebocontrolled, parallel groups, phase 2/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS).

The objective was to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS).

Overall enrolment: 394 patients (EU, North and South Americas)

Read more on the results

 

Read more on clinicaltrials.gov Read more on clinicaltrialsregister.eu